MYGNMyriad Genetics, Inc.

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 22.3% gain over the past six months, beating the S&P 500 by 11.2 percentage points.

Myriad Genetics (MYGN) is back in focus after its second quarter 2026 earnings missed expectations and the company cut its full year revenue guidance, moves that triggered a sharp selloff in the stock. See our latest analysis for Myriad Genetics. For investors tracking Myriad Genetics over a longer horizon, the recent earnings miss and lower 2026 revenue guidance have accelerated an already weak trend. The 1-day share price return of down 46.74% adds to a year-to-date share price decline of...

Investors became less willing to wait for companies’ long-term plans when those businesses continued to face problems delivering results in the short term.

In late July 2026, Myriad Genetics reported second-quarter 2026 results showing sales of US$190.7 million and a reduced net loss of US$43.2 million, while also lowering full-year 2026 revenue guidance to US$770 million–US$790 million due to weaker prenatal health test volumes and more cautious expectations for revenue per test. At the same time, Myriad’s longstanding partnership with Burning Rock Biotech advanced with a new global HRD technology licensing agreement, underscoring how...

Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 46.1% in the afternoon session after the company reported disappointing second-quarter 2026 results that missed Wall Street's expectations and included a reduced full-year forecast.

Myriad Genetics (NASDAQ:MYGN) reported second-quarter 2026 revenue of $190.7 million, down 11% from a year earlier, as a 1% decline in total test volume and a 9% decrease in revenue per test weighed on results. The company lowered its full-year revenue and gross-margin outlook and suspended adjusted

Myriad Genetics faces significant reimbursement headwinds, lowering full-year 2026 revenue guidance to $770-$790 million while advancing key pipeline milestones and strategic initiatives.

Myriad (MYGN) delivered earnings and revenue surprises of -733.33% and -7.12%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Genetic testing company Myriad Genetics (NASDAQ:MYGN) fell short of the market’s revenue expectations in Q2 CY2026, with sales falling 10.5% year on year to $190.7 million. The company’s full-year revenue guidance of $780 million at the midpoint came in 9.7% below analysts’ estimates. Its non-GAAP loss of $0.25 per share was significantly below analysts’ consensus estimates.

Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.

Myriad Genetics has been treading water for the past six months, recording a small loss of 3.6% while holding steady at $5.66. The stock also fell short of the S&P 500’s 8.6% gain during that period.

Quest Diagnostics (NYSE:DGX) reported double-digit revenue growth and raised its full-year 2026 outlook after what executives described as strong demand across its physician, hospital and consumer channels, as well as increased volume from major collaborations with Corewell Health and Fresenius Medi

Genomics is reshaping healthcare, and these three stocks - MYGN, SANA and WVE - stand out as rapid advances in personalized medicine and synthetic biology continue to transform the industry.

Aspira and Myriad Genetics take different approaches to women's health diagnostics, but which stock looks more compelling now? Let's dive in.

Myriad Genetics expands its testing portfolio and advances its Cancer Care Continuum strategy. Can reimbursement risks and cost pressures temper growth?